Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Cancer cells use tactics to avoid being recognised by immunotherapy agents

Cancer cells use tactics to avoid being recognised by immunotherapy agents

Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy agents.

Image: Colour-enhanced image of human colon cancer cells in culture. Credit: Annie Cavanagh. License: (CC BY 4.0)

Image: Colour-enhanced image of human colon cancer cells in culture. Credit: Annie Cavanagh. License: (CC BY 4.0)

This may provide clues as to why some of the patients do not respond to immunotherapy agents say researchers. Researchers have also suggested methods by which this could be bypassed and effectiveness of immunotherapy could be increased. The results of the study were published this week in the latest issue of the Journal for Immunotherapy of Cancer.

Researchers from the Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust explain that cancer cells can literally “change their spots” so that they are unrecognizable to the immunotherapy agents. They can do this by switching off the key molecules on their surfaces that the immunotherapy agents are trained to recognize.

The team tested samples of bowel cancer cells and found that while some responded well to immunotherapy, others failed to do so. They tested the changes in these tumour cells by examining miniature tumours grown in the labs. The team then tried a combination of available agents to reverse the efficacy of the immunotherapy agents so that they could work for more patients.

The researchers explain that the antibody-based drug cibisatamab – an immunotherapy agent, could work better in more patients if the theory is proved. This study, they add, could also help determine which of the patients would respond well to immunotherapy and which of them would not.

Cibisatamab is one of the new and promising immunotherapy agents that can help identify the cancer cells using immune mechanisms and then kill them selectively. However some patients respond well to this drug while others respond poorly or not at all. Researchers explain that one arm of the drug attaches itself to a molecule present on the surface of the cancer cell. It is called carcinoembryonic antigen (CEA). The other arm of the drug activates a special immune cell called a T cell that can attack and kill the tumour cell. When grown in the labs the team found that some of the tumour cells could hide themselves from treatment by changing their surface molecules and the CEA levels thus reduce.

Cibisatamab has been found to be effective against most bowel cancer patients. This study aimed to look at the cause of its non-efficacy in some of the patients. Biopsy samples were taken from eight bowel cancer patients for this study and mini replicas of the tumours were created in the labs of ICR. Some of the cells contained high numbers of CEA, some low and some were in between, explain the researchers. The team then used cibisatamab to treat these patients and saw that 96 percent of those with high CEA responded well with the drug and only 20 percent with low CEA responded to the drug. They noted that 53 percent of those with mixed levels of CEA responded to the drug.

As a next step the team allowed the cancer cells to grow again in the lab for a month. They noticed that the CEA levels had changed in these regrown tumours. This meant that the cells could change their CEA so as to escape being recognized by the immunotherapy agent. The researchers delved deeper into the genetic make-up of the cells with low CEA on their surfaces and found that these cells have an increase in the WNT pathway of genes. Certain drugs target this pathway in the cancer cells. They realized that if these drugs were combined with cibisatamab, the efficacy of the cibisatamab could be improved in the cancer cells. WNT pathway targeting drugs include tankyrase inhibitors and porcupine inhibitors. They found that when these drugs were used the CEA levels on the cells were increased. This made them vulnerable to the immunotherapy, explained the researchers.

Dr Marco Gerlinger, Team Leader in Translational Oncogenomics at The Institute of Cancer Research, London, and Consultant Oncologist at The Royal Marsden said in a statement, “Cancer is very good at hiding from the body’s immune system. The latest successful immunotherapies work by acting as a matchmaker to bring the immune system together with cancer, so that it can see it and attack it.” He explained, “Our study has found that bowel cancers have a way of dodging even the newest of immunotherapies – changing their spots by altering the levels of a key molecule on the surface of cells, so that they become harder to recognise. We used a new technique for growing miniature replicas of tumours to develop a way of testing whether patients will respond to immunotherapy. And best of all, we were able to identify an existing inhibitor of the WNT pathway which could be used to reverse this process. We hope that this could in future help immunotherapies work in more patients, by making cancer cells more visible to immune cells.” He was the study leader.

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, added, “As we move away from one-size-fits-all therapy for cancer, it’s so important that we are able to identify which patients are most likely to respond to a drug, and do everything we can to avoid resistance to treatment for as long as possible. This research reveals a way in which cancers are able to hide from a promising new type of immunotherapy. Although the work is still in its early stages, it could be used to develop a test for who is most likely to respond to the drug, and points to possible drug combinations that might prevent or delay resistance.”

The study was funded by the Cancer Research UK and the NIHR Biomedical Research Centre at The Institute of Cancer research (ICR) and The Royal Marsden.

Tagged with:

About author

Related Articles